News

Itching negatively impacts patients’ quality of life and work productivity in PBC, but there is currently no way to manage it effectively.

Peroxisome proliferator-activated receptor (PPAR) agonists appear to be a safe and effective therapeutic alternative for patients with PBC.

In a postmarketing clinical trial, patients with noncirrhotic PBC receiving Ocaliva showed significantly higher rates of liver transplant and death.

For patients, these initiatives mean greater visibility for their condition, more resources to navigate care, and stronger bonds with others who understand their experience.

A new study finds that verbal suggestions about a task can influence how willing people with PBC may be to persist through fatigue.

A recent study utilized genetic markers demonstrate that individuals with higher BMI may have a higher risk of developing PBC.

The Western Pacific region experienced a marked increase in PBC prevalence in the last year, notes a new study.

Women with primary biliary cholangitis (PBC) showed lower testosterone and more inflammatory T cells compared to women without the disease.

A study found that PBC appears to increase the risk of colon polyps or colorectal cancer.

A relatively new therapy, seladelpar, has an acceptable efficacy and safety profile in the treatment of PBC.